The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Without the details ,it’s not feasible to be specific or take a clear view on WN.
As an ex ICI/ Zen. However I’d say just bide your time...it’s steady away. FDA are likely to have solution view,particularly for a long termer drug Iclaprim shows superior position over Vanomyin , hence potential cannot be dismissed. Also most liver impacts are idiosyncratic ( ie not specifically drug impacted).
Amphions other projects are significant also.
decent recovery
If they have blood samples stored from all patients these could potentially be analysed for biochemistry to prove liver function either way. Just imo
on the ask ...this is not a duster
Do they have funds to do more research and who will fund them?
Few questions
Motif Bio Plc (LON:MTFB, NASDAQ:MFTB) said it has requested a meeting with the Food & Drug Administration after the US watchdog said it wouldn’t be giving the regulatory green light to the company’s antibiotic, iclaprim.
In what’s called a complete response letter, the FDA indicated additional data would be required “to further evaluate the risk for liver toxicity” before granting approval.
–– ADVERTISEMENT ––
Motif, which developed the treatment for acute bacterial skin and skin structure infections, said it is keen to “to discuss potential options to address the deficiencies”. According to chief executive Graham Lumsden, his team may have to wait between 30-45 days before having the opportunity to do so.
"We look forward to working with the agency to discuss options to advance iclaprim towards approval," he said.
exactly this is what i can see delayed no rejected
Nice one dnd .
Nice on Gil
Well I put 1.5k in
Dnd someone who will have 20k in near future .
That’s around 1.2% of AMP.
Who just bought ten grand worth of this stock
Yes. Amp had the leverage initially if it were to multibag Now Motif is in the far better position as Amp must be in dire straits now.
can,t believe this came down as low as 0.225
It’s all down to Motif once again. Amps £20m plus debts were secured with £10m worth of Motif shares. This morning their Motif shares are worth around £1m.
Naked says to sell. At this time if people want to catch the bounce they might make a few quid by buying and trying to get out with a. Small profit. I’ve made most of my profits from the ones that open with huge drops. It might be the case with this. But now the fundamentals as a rational investment are long gone. It’s obly for a short term gamble. Good luck
Why would people not , maybe drop was over done a tad .
I can’t see how this could ever recover. It’s main asset being Motif. They already have £20m plus debt which they can’t service and they have just reduced their assets by over £9m this morning
people are still buying this after this horror news????....well, some have to much money to loose...crazy world we are living :)
Gilo. Are you just buying for the dead cat bounce ?
out of curiousity, which broker allows you to trade? MTFB and AMP are in non-dealable state in IG
May recover... uncertain at the moment
Bit like Blue star capital !!!!